End-to-End One-Pot Preclinical Immunoaffinity-Liquid Chromatography-Tandem Mass Spectrometry Workflow for Simultaneous Quantitation of Total and Conjugated Antibody Levels of Antibody-Drug Conjugates with Protease-Cleavable Linkers
Analytical Chemistry · 2025
DOI: 10.1021/acs.analchem.5c01374 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytical Chemistry, 2025. Verfasst von Vikram M Shenoy und 5 weiteren Autor:innen. Beteiligte Einrichtung: Quantitative, Translational, and ADME Sciences, AbbVie Inc., South San Francisco, California 94080, United States. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Immunoconjugates, Immunoglobulin G, Chromatography, Affinity. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The share of the oncology drug pipeline represented by antibody-drug conjugates (ADCs) continues to grow at a remarkable pace. To support the preclinical screening and characterization of early ADC candidates at scale, innovative bioanalytical approaches that improve turnaround times and data quality are sorely needed. This article presents a novel, streamlined one-pot immunoaffinity-liquid chromatography-tandem mass spectrometry (LC-MS/MS) workflow employing proteinase K for the simultaneous quantitation of total and conjugated antibody levels in human IgG1-based ADCs with protease-cleavable linkers by generating both surrogate analytes in a single digestion. Peptide mapping was used to select a sensitive and selective surrogate peptide, followed by optimization of reaction pH, temperature, and digestion time. The method was qualified according to nonregulated acceptance criteria and demonstrated robust linearity, accuracy, and precision, performing comparably to the conventional trypsin assay in both toxicokinetic and pharmacokinetic studies. Real-world applications highlighted the utility of this method as a sound alternative when troubleshooting the trypsin assay. By consolidating a dual-protease workflow into a single-protease workflow, this one-pot assay minimizes sample handling and variability, reduces the usage of samples and consumables, and increases LCMS uptime by halving the number of samples to be analyzed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Quantitative, Translational, and ADME Sciences, AbbVie Inc., South San Francisco, California 94080, United States.
- Quantitative, Translational, and ADME Sciences, AbbVie Inc., Worcester, Massachusetts 01605, United States.
- Quantitative, Translational, and ADME Sciences, AbbVie Inc., North Chicago, Illinois 60044, United States.
ORCID-Profile: Vikram M Shenoy
Zitieren
APA
Shenoy, V. M., Abarca, R., Biondi, C. A., Ma, J., Li, Y., & Sarvaiya, H. (2025). End-to-End One-Pot Preclinical Immunoaffinity-Liquid Chromatography-Tandem Mass Spectrometry Workflow for Simultaneous Quantitation of Total and Conjugated Antibody Levels of Antibody-Drug Conjugates with Protease-Cleavable Linkers. Analytical Chemistry. https://doi.org/10.1021/acs.analchem.5c01374
Vancouver
Shenoy VM, Abarca R, Biondi CA, Ma J, Li Y, Sarvaiya H. End-to-End One-Pot Preclinical Immunoaffinity-Liquid Chromatography-Tandem Mass Spectrometry Workflow for Simultaneous Quantitation of Total and Conjugated Antibody Levels of Antibody-Drug Conjugates with Protease-Cleavable Linkers. Analytical Chemistry. 2025. doi:10.1021/acs.analchem.5c01374
BibTeX
@article{Shenoy2025,
author = {Shenoy, Vikram M and Abarca, Radek and Biondi, Chris A and Ma, Junli and Li, Yihan and Sarvaiya, Hetal},
title = {End-to-End One-Pot Preclinical Immunoaffinity-Liquid Chromatography-Tandem Mass Spectrometry Workflow for Simultaneous Quantitation of Total and Conjugated Antibody Levels of Antibody-Drug Conjugates with Protease-Cleavable Linkers},
journal = {Analytical Chemistry},
year = {2025},
doi = {10.1021/acs.analchem.5c01374}
}
EUVIMED